Armacokinetic profile. Translation in two advanced BC patients, resulted in no unwanted side effects, confirming prior observations around the biosafety of radiotracers based on the potent GRPR-antagonist [DPhe6 ,LeuNHEt13 ]BBN(6-13) and on GRPR-antagonist radioligands generally. Additionally, it revealed the capability of [99m Tc]Tc-DB15 to detect a number of metastatic BC lesions, both within the skeleton and in soft tissues, but these findings should be confirmed prospectively within a committed human study. In view of your above, additional clinical evaluation seems to become warranted to establish the diagnostic value of [99m Tc]Tc-DB15 in BC, Pc, as well as other GRPR-expressing human malignancies.Supplementary Components: The following are readily available on the net at https://www.mdpi.com/article/ ten.3390/cancers13205093/s1, Figure S1: Typical radiochromatogram of HPLC analysis of [99m Tc]TcDB15 (preclinical); Figure S2: Typical radiochromatogram of HPLC evaluation of [99m Tc]Tc-DB15 (for individuals); Figure S3: Complete body scan three h pi of [99m Tc]Tc-DB15 in patient 1 (with anterior and posterior projection); Figure S4: PET/CT 1 h pi of [18 F]FDG in patient 1; Table S1: Numerical biodistribution information for [99m Tc]Tc-DB15 in PC-3 xenograft-bearing SCID mice at 1, four and 24 h pi; Table S2: Numerical biodistribution data for [99m Tc]Tc-DB15 in T-47D xenograft-bearing SCID mice at 1, four and 24 h pi.Cancers 2021, 13,12 D-Isoleucine Protocol ofAuthor Contributions: Conceptualization, B.A.N., R.M. and T.M.; methodology, B.A.N., A.K., P.K., B.J., B.B., D.I. and T.M.; validation, B.A.N., R.M., R.C., D.I. and T.M.; investigation, B.A.N., A.K., P.K., B.J., B.B., R.C., D.I. and T.M.; sources, R.M., R.C. and T.M.; information curation, P.K., R.M., R.C. and T.M.; writing–original draft preparation, T.M.; writing–review and editing, all co-authors; supervision, B.A.N., R.M., R.C. and T.M.; project administration, R.M., R.C. and T.M.; funding acquisition, R.M., R.C. and T.M. All authors have read and agreed for the published version from the manuscript. Funding: The preclinical study was co-financed by Greece and also the European Union (European Regional Improvement Fund) by way of the project “NCSRD–INRASTES investigation activities within the framework on the national RIS3” (MIS 5002559), implemented under the “Action for the Strategic Improvement around the Analysis and Technological Sector”, funded by the Operational Program “Competitiveness, Entrepreneurship and Innovation” (NSRF 2014-2020). Additional assistance was offered by Siemens AG by way of the project stablishing a Multidisciplinary and Efficient Innovation and Entrepreneurship Hub(E-11928). The preparation of the Aligeron References radioligand for the patient study was supported by the CERAD project, financed under Sensible Development Operational Plan 2014020, Priority IV, Measure 4.2. POIR.04.02.004-A001/16. The clinical a part of the study obtained monetary support from the Poznan University of Health-related Sciences (grant No. 502-14-22213550-41147). Institutional Evaluation Board Statement: The animal and patient studies had been conducted as outlined by the guidelines of the Declaration of Helsinki. The animal protocols were approved by the Division of Agriculture and Veterinary Service with the Prefecture of Athens (protocol numbers #1609 for the stability and #1610 for the biodistribution research, both issued on 11 April 2018). The patient study protocol was authorized by the Bioethical Committee with the Poznan University of Medical Sciences (decision no. 1153 issued on 16 January 2020). Informed Consent Statement: Patients gave th.
